According to @Reuters, the US Treasury Department is drafting rules to permit most US-China pharmaceutical licensing deals, excluding those linked to weaponizable pathogens or biotechnology. This approach, supported by major drugmakers like Pfizer, marks a departure from tighter restrictions advocated by some lawmakers; watch for final rule details ahead of the upcoming Trump-Xi meeting.

Pfizer

Twitter Wire | US weighs allowing most pharma licensing deals with China, sources say

Bio-pharmaceutical stocks fell in premarket trading after capital rotation from small- and mid-cap biotechs to large-cap healthcare names amid sector consolidation, with Gilead Sciences down 1.0%, Pfizer falling 0.1% and Merck sliding 0.3%.

Pfizer Canada: Vaccine will be available through various distribution channels in coming days and weeks

Pfizer Canada: Vaccine will be available through various distribution channels in coming days and weeks

Health Canada authorizes Pfizer and BioNTech's Omicron XFG-adapted COVID-19 vaccine

BioNTech

Health Canada authorizes Pfizer and BioNTech's Omicron XFG-adapted COVID-19 vaccine

Pfizer's 15-minute chart has exhibited Bollinger Bands Narrowing, coupled with a KDJ Death Cross at 09/15/2026 15:00. This indicates a decline in the magnitude of stock price fluctuations and a shift in momentum towards the downside, with potential for further decreases.On September 15, 2026, at 15:00, technical indicators for Pfizer Inc. (PFE) suggest a potential bearish trend. The 15-minute chart shows narrowing Bollinger Bands, signaling a reduction in price volatility and a [possible consolidation phase][1]. Concurrently, the KDJ indicator has formed a death cross, with the K line crossing below the D line, indicating weakening momentum and a [potential shift in market sentiment][2]. These patterns collectively suggest a possible continuation of downward movement in the near term. Investors are advised to monitor subsequent price action and volume for confirmation of the trend. As always, technical indicators should be used in conjunction with broader market analysis and risk management strategies.

辉瑞

Pfizer's 15-minute chart shows Bollinger Bands narrowing and KDJ death cross.

Catalyst<ul> <li>Recent MACD Death Cross signal indicates potential bullish momentum for PFE.</li> <li>The company maintains strong profitability metrics including fixed assets turnover and net profit margin.</li></ul>Risk<ul> <li>Repeated RSI Overbought signals suggest bearish pressure on PFE.</li> <li>Net fund outflows are observed across small, medium, large, and extra-large order sizes.</li></ul>

Key Factors

Pfizer licensed an experimental obesity pill from YaoPharma and a weight-loss injection from Sciwind Biosciences, securing potential milestone payments totaling nearly $2.4 billion.Health Canada authorized the Pfizer and BioNTech updated Omicron XFG COVID-19 vaccine, with distribution planned for the coming days and weeks.

PFE News